Optiscan files FDA submission for InSpecta imaging device, targeting massive US veterinary market. The company submitted its regulatory dossier for the InSpecta digital microscopic imaging system, marking a critical step toward US market entry. The US veterinary market is valued at approximately US$11.92 billion and is projected to grow at 8.7% annually through 2030. InSpecta provides real-time, non-invasive imaging for animal applications, addressing growing demand for advanced veterinary care. The FDA submission establishes a regulatory pathway that strengthens discussions with potential customers and partners while creating a framework for future device submissions across Optiscan's portfolio. With over 136 million dogs and cats in US households, demand for complex veterinary treatments continues to rise, positioning Optiscan to capture significant market opportunity.
